Efficacy, safety, and adverse effects of finasteride and dutasteride in treating benign prostatic hyperplasia: A retrospective cohort study
DOI:
https://doi.org/10.15218/zjms.2024.33Keywords:
Adverse, Benign prostatic hyperplasia, Dutasteride, Finasteride, VolumeAbstract
Background and objective: Symptomatic benign prostatic hyperplasia (BPH) results in several symptoms including the lower urinary tract symptoms. Consequently, BPH may affect the bladder and finally the kidneys. There are various pharmacological options for the treatment of BPH including 5-Alpha Reductase Inhibitors (5-ARIs) (finasteride or dutasteride). Recent researchers have demonstrated that using 5-ARIs for treating BPH may have unfavorable adverse effects. Therefore, this study aimed to compare finasteride and dutasteride in terms of their efficacy, safety, and adverse effects.
Methods: This retrospective cohort study included 170 patients, 77 patients who received finasteride and 93 patients who received dutasteride, the data obtained retrospectively from medical databases and file sheets were reviewed and selected according to inclusion and exclusion criteria followed by the comparison between two groups regarding baseline characteristics, prostate volume and the incidence of adverse effects.
Results: Similarity observed between two groups at baseline characteristics. Statistically, no significant differences were identified between dutasteride and finasteride in the reduction of prostate volume. However, dutasteride and finasteride significantly reduced prostate volume at 1-year follow-up. No significant differences were observed between two agents regarding the incidence of adverse effects.
Conclusion: Finasteride and dutasteride improved lower urinary tract symptoms (LUTS) at one-year follow-up by reducing prostate volume. The incidence rate of adverse effects for finasteride and dutasteride was similar over one year.
Metrics
References
Bortnick E, Brown C, Simma-Chiang V, Kaplan SAJ. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol 2020; 12:17. doi: 10.1177/1756287220929486.
Foo KTJ. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol 2019; 37(7):1293–6. doi: 10.1007/s00345-019-02691-0
Heidari M, Hadi AJ. Relationship between Serum Level of Vitamin D in patients with BPH compared to healthy people in age group over 45. Pak J Med Health Sci 2020; 14(2):1376–80.
Kim EH, Brockman JA, Andriole GLJ. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J Urol 2018; 5(1):28–32. doi: 10.1016/j.ajur.2017.11.005
Nettleton J, Jones P, Pietropaolo A, Geraghty R, Rai B, Drake M, et al. The industrial revolution for the management of benign prostate obstruction: worldwide publication trends for surgical and medical therapies over the past two decades. Cent European J Urol 2019; 72(2):149. doi: 10.5173/ceju.2019.1876
Bauer SR, Harrison SL, Cawthon PM, Senders A, Kenfield SA, Suskind AM, et al. Longitudinal Changes in Adiposity and Lower Urinary Tract Symptoms Among Older Men. J Gerontol A Biol Sci Med Sci 2021. doi: 10.1093/gerona/glab227
Fogaing C, Alsulihem A, Campeau L, Corcos JJM. Is early surgical treatment for benign prostatic hyperplasia preferable to prolonged medical therapy: pros and cons. Medicina 2021; 57(4):368. doi: 10.3390/medicina57040368
Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE, et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Trans androl urol 2019; 8(5):529. doi: 10.21037/tau.2019.10.01
Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Medium-and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol 2016; 27(8):1115–22. doi: 10.1016/j.jvir.2016.04.001
Kaplan SAJ. The Effects of Dutasteride and Finasteride on BPH-Related Hospitalization, Surgery and Prostate Cancer Diagnosis: A Record-Linkage Analysis. World Jurol 2014; 192(5):1493. doi: 10.1007/s00345-012-1000-4
Dhingra N. Steroidal 5α-Reductase: A Therapeutic Target for Prostate Disorders. Oxidoreductase: Intech Open. Intech Open 2021. doi: 10.5772/intechopen.95809
Nemane ST, Bhusnure OG, Gholve SB, Mitakari PR, Karwa PNJ. Therapeutics. A Review on Finasteride: A 5-Alpha Reductase Inhibitors, its Mechanism, Facts and Benefits. J Drug Del Thera 2019; 9(3-s):1132–6. doi: 10.22270/jddt.v9i3-s.3013
Drobnis EZ, Nangia AK. 5α-Reductase inhibitors (5ARIs) and male reproduction. Impacts of Medications on Male Fertility. Adv Exp Med Biol 2017; 1034:59–61. doi: 10.1007/978-3-319-69535-8_7
Deng T, Lin X, Duan X, He Z, Zhao Z, Zeng GJP. Prostate cancer patients can benefit from 5-alpha-reductase inhibitor treatment: a meta-analysis. Peer J 2020; 8:e9282. doi: 10.7717/peerj.9282
Banerjee PP, Banerjee S, Brown TR, Zirkin BRJ. Androgen action in prostate function and disease. Am J Clin Exp Urol 2018; 6(2):62. PMID: 29666834
Zhou Z, Cui Y, Wu J, Jin HJE, Medicine T. Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta analysis of randomized controlled trials. Ex Ther Med 2020; 20(2):1566–74. doi: 10.3892/etm.2020.8851
Aminova MJT. Can Androgenetic Alopecia be Reversed and What Are the Effective Treatments? The Science Journal of the Lander College of Arts and Sciences 2022; 15(2):27–35.
Fu Y, Han S, Wang L, Gao W, Wu E, Cao X, et al. Comparison of characteristics of benign prostatic hyperplasia (BPH) patients treated with finasteride and alpha blocker combination therapy versus alpha blocker monotherapy in China: an analysis of electronic medical record data. Adv Ther 2018; 35(8):1191–8. doi: 10.1007/s12325-018-0748-3
Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride. Peer J 2017; 5:e3020. doi: 10.7717/peerj.3020
Saengmearnuparp T, Lojanapiwat B, Chattipakorn N, Chattipakorn SJB, Pharmacotherapy. The connection of 5-alpha reductase inhibitors to the development of depression. Biomed Pharmacother 2021; 143:112100. doi: 10.1016/j.biopha.2021.112100
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen MLJT. Adverse side effects of 5α‐reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011; 8(3):872–84. doi: 10.1111/j.1743-6109.2010.02157.x
Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M, Medina-López R, Ruiz-Cerdá JL, Rodríguez-Rubio F, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study. Int Urol nephrol 2016; 48(5):645–56. doi: 10.1007/s11255-015-1206-7
Kaplan SAJ. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). J Urol 2012; 187(2):584–5. doi: 10.1016/j.juro.2011.10.106
Li Y, Ma J, Qin X-H, Hu C-Y. The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis. Transl Androl Urol 2022; 11(3):313. doi: 10.21037/tau-22-58
Silva MHA, Souza JA. Vulnerability of patients with prostatic hyperplasia treated with dutasteride and finasteride. Revista Bio 2021; 29:394–400. doi: 10.1590/1983-80422021292477.
Nguyen D-D, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA dermatol 2021; 157(1):35–42. doi: 10.1001/jamadermatol.2020.3385
Andrade CJT. Why odds ratios can be tricky statistics: the case of finasteride, dutasteride, and sexual dysfunction. J Clin Psychiatry 2018; 79(6):22473. doi: 10.4088/JCP.18f12641
Giatti S, Foglio B, Romano S, Pesaresi M, Panzica G, Garcia-Segura LM, et al. Effects of subchronic finasteride treatment and withdrawal on neuroactive steroid levels and their receptors in the male rat brain. Neuroendocrinology 2016; 103(6):746–57. doi: 10.1159/000442982
Favilla V, Cimino S, Alessio P, Volti GL, Russo G, Trovato F, et al. Neuroactive steroid levels in cerebrospinal fluid of patients treated with dutasteride: A case-control study. Europ Urol Suppl 2019; 18(1):e252. doi: 10.1016/S1569-9056(19)33588-2
Barkin JJ. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol 2011; 18(1):14. PMID: 21501546.
Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108(3):388–94.doi: 10.1111/j.1464-410X.2011.10195.x
Favilla V, Russo GI, Privitera S, Castelli T, Giardina R, Calogero AE, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male 2016; 19(3):175–81. doi: 10.1080/13685538.2016.1195361
Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui YJCiia. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interven Aging 2019; 14:399. doi: 10.2147/CIA.S192435
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Euro Urol 2010; 57(1):123–31. doi: 10.1016/j.eururo.2009.09.035
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Wishyar Al Bazzaz (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in Zanco J Med Sci is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0).
